Q32 Bio Inc. (QTTB) Stock: Price, Forecast & Analyst Target
Q32 Bio Inc. (QTTB) — MoonshotScore 60/100 (Fair band), calculated Nov 18, 2026. Price $8.34 (-1.65%), as of the Nov 20, 2026 trading session; market cap $250M.
Educational signal · not a buy or sell recommendation · How to read this
Q32 Bio Inc. · QTTB · NASDAQ
is a clinical-stage biotechnology company focused on developing biologic therapeutics for autoimmune and inflammatory diseases.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Q32 Bio (QTTB)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, at a cheap price. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Fortress; Valuation: Cheap; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $54M (Q4 FY2025, quarter ended Dec 2025)
- EPS beat 1 of the last 4 reports
- Altman Z 16.66 · Piotroski F 5
Helping: business quality, balance-sheet strength, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 59 | Fair | |
| 59 | Fair | |
| 59 | Fair | |
| 60 | Fair | |
| 60 | Fair | |
| 60 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $8.34 | |
| Change on the day | -1.65% | |
| Market capitalisation | $250M | — |
| Price / earnings (trailing) | 2.76 | |
| Shares traded on the day | 476.7K |
Price & events
Other perspectives
Council score for Q32 Bio (QTTB): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Q32 Bio (QTTB), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Q32 Bio Inc. (QTTB) is listed on NASDAQ. It employs 25 people. In Q4 FY2025 it reported revenue of $54M and net income of $58M. The market values it at $250M.
What do the latest results show for Q32 Bio (QTTB)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $54M. Against analyst estimates the company has EPS beat 1 of the last 4 reports.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $54M | $58M | — |
What are the financial strengths and risks for Q32 Bio (QTTB)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength, an attractive price, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 16.66 · Piotroski F 5. Trailing ratios: ROE 24.0% · ROA 6.5% · current ratio 56.34.
What should you watch next at Q32 Bio (QTTB)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $285,714 · EPS -1.36 · 6 analysts. Current published price targets run low $14.00 · high $66.00 · consensus $36.50 · median $35.00 against a quoted price of $8.34 (as of Nov 20, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q4 FY2025) was filed Mar 10, 2026 — 8 months ago.
Checked against the records this page reads, on the dates shown above.
How does Q32 Bio compare with its peers?
Short answer
Q32 Bio's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1347.11 Nov 20, 2026 | $1.20T | 98 5-pillar Nov 18, 2026 | |
| $923.34 Nov 19, 2026 | $95.5B | 95 5-pillar Nov 18, 2026 | |
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $438.82 Nov 19, 2026 | $237B | 84 5-pillar Nov 18, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 18, 2026 | |
| $15.47 Nov 20, 2026 | $86.6M | 82 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| Q32 Bio (QTTB) — this page | $8.34 | $250M | 60 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $14.00 – $66.00
- Consensus target
- $36.50
- Median target
- $35.00
- Revenue estimate
- $285,714
- EPS estimate
- $-1.36
Consensus record · Captured .
Measured against a quoted price of $8.34 (as of Nov 20, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held QTTB in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported QTTB in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Q32 Bio (QTTB)
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for QTTB?
QTTB carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is QTTB a good stock to buy?
Stock Expert AI does not rate QTTB buy, sell or hold. Q32 Bio Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the QTTB stock price today?
The last price recorded for Q32 Bio Inc. (QTTB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the QTTB price target?
The analyst consensus price target for Q32 Bio Inc. (QTTB), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key factors to evaluate for QTTB?
(QTTB) holds a MoonshotScore in the moderate range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Not financial advice.
How frequently does QTTB data refresh on this page?
QTTB's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven QTTB's recent stock price performance?
(QTTB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline of biologic therapeutics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider QTTB overvalued or undervalued right now?
(QTTB) trades at 2.76x earnings. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of QTTB?
Fractional-share availability for Q32 Bio Inc. (QTTB) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 21 figures on this page — 14 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com